NCT01134666 2017-06-09
An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer
Merck KGaA, Darmstadt, Germany
Terminated
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany